SK hynix's $28 Billion Listing Leads a Wave of Equity Issuance Testing Market Absorption

The US equity market is running a live experiment in how much new stock it can absorb at once. SK hynix prices a $28.1 billion Nasdaq listing on Thursday — the largest share sale by a foreign company in American history. Rivian raises $1.32 billion in a dilutive follow-on the same week. Behind those two headline deals sits a broader pipeline of IPOs and secondaries that, by Goldman Sachs’ estimate, pushes net equity supply to roughly flat in 2026 — the first time that figure has not been negative since 2003.

The question is not whether the issuance is real. It plainly is. The question is whether the market’s demand-side plumbing can handle it without indigestion — and whether the two-decade mechanical tailwind of shrinking share counts is genuinely over, or merely pausing before buyback firepower reasserts itself.

SK hynix: The $28 Billion Test Case

SK hynix, South Korea’s dominant high-bandwidth memory (HBM) supplier and a critical node in the AI accelerator supply chain, is selling 17.8 million American Depositary Receipts at $158.14 per share through lead underwriters BofA and Citi, raising approximately $28.1 billion{{cite:f63cb28b7b14}}. The deal is oversubscribed, according to multiple press reports, and the ADRs are set to begin trading on Nasdaq on July 10 under the ticker SKHY{{cite:03c30d2e34df}}.

By deal size, this is the second-largest share sale ever, behind only Saudi Aramco’s 2019 IPO. It is the largest US listing by a foreign company. UBS reportedly recommends buying the ADR over the Korean-listed ordinary shares, citing accessibility and liquidity for global investors{{cite:03c30d2e34df}}.

The strategic logic is straightforward: SK hynix controls the majority of the global HBM market — the specialized stacked memory that sits inside every major AI accelerator — and is monetizing that position at a moment when AI infrastructure spending is at peak intensity. The company is effectively asking public markets to fund its next capacity expansion cycle, and investors are signaling willingness to supply the capital.

What makes this deal a structural event rather than just a large listing is its context. It arrives in a year where Goldman Sachs expects total IPO proceeds to reach a record $225 billion, with sixty US companies already having gone public year-to-date and raised nearly $40 billion through late June{{cite:ca3a9226238c}}. The pipeline behind SK hynix includes Csquare (CSQR), a $1.25 billion deal backed by Morgan Stanley and TD Securities; Standard Nuclear (STDN), a $356 million offering led by BofA and Goldman; and a steady stream of SPACs and smaller biotech listings{{cite:f63cb28b7b14}}.

The Secondary Surge: Rivian Leads a Crowded Calendar

The same week SK hynix prices its IPO, the follow-on market is equally active — and in some cases, equally punishing for existing shareholders.

Rivian Automotive (RIVN) priced 75 million shares of common stock at $15.50 per share on July 8, raising approximately $1.16 billion in gross proceeds, with underwriters holding a 30-day option for an additional 11.25 million shares that could bring total proceeds to roughly $1.32 billion{{cite:644f9e78521a}}. The offering was timed to capitalize on a rally driven by stronger-than-expected Q2 delivery numbers and a raised full-year outlook, but the market read it as dilution rather than a vote of confidence: RIVN shares fell 18% on July 7 when the offering was announced{{cite:644f9e78521a}}. The stock closed at $16.66 as of July 8{{cite:9d817bdc4b54}}.

Rivian is far from alone. The early-July secondary calendar includes:

Sources: SEC filings and company press releases{{cite:1de67fe26c4d}}.

The pattern is familiar to anyone who watched the 2021 issuance cycle: companies raise capital when their stocks are up, and the market prices in dilution immediately. What is different in 2026 is the scale and the concentration. These are not scattered micro-cap raises; several are billion-dollar-plus transactions landing in the same week as a $28 billion IPO.

The Structural Backdrop: A 23-Year Tailwind Under Stress

The deeper story sits in the arithmetic of net equity supply — new shares issued minus shares removed through buybacks, go-privates, and M&A. Goldman Sachs data shows that figure has been negative every year since 2003, meaning the corporate sector has consistently removed more equity from the market than it has added. That mechanical shrinkage supported stock prices through two bull markets, a pandemic, and an AI boom: when the denominator (shares outstanding) contracts, the same earnings support a higher per-share price.

In 2026, Goldman projects net equity supply turns approximately flat — and turns meaningfully positive in 2027 as lock-up periods on this year’s landmark listings begin to expire{{cite:ca3a9226238c}}.

The driver is not just IPO volume. It is a simultaneous reversal in corporate buyback behavior. Alphabet (GOOGL) raised nearly $85 billion in a secondary equity offering to fund its AI infrastructure buildout — the company’s first net equity issuance in 11 years{{cite:ca3a9226238c}}. Meta Platforms (META) is reportedly preparing a similarly sized offering{{cite:ca3a9226238c}}. The four largest hyperscalers — Alphabet, Amazon, Meta, and Microsoft — have collectively announced $725 billion in planned AI infrastructure investment{{cite:ca3a9226238c}}. When internal cash flow cannot fund that spending, equity markets become the funding source.

Barclays’ global research chair, Ajay Rajadhyaksha, framed the shift bluntly: “This is a sea change. It will give us a clean test case for how much of the broad stock rally over the past decade has been about a net reduction in shares.”{{cite:ca3a9226238c}}

Deutsche Bank has echoed the concern, warning that AI capital expenditure is beginning to crowd out share buybacks — a quiet erosion of one of the steadiest sources of equity demand{{cite:d9286ca213ed}}.

The Counterargument: Buybacks Still Exceed Issuance

For every structural bear, there is a base-rate rebuttal — and UBS has made the most coherent one.

In a June 22 research note, UBS estimated that 2026 IPO issuance is on track for $200–350 billion, with secondary offerings potentially exceeding $400 billion — both record highs in absolute dollar terms{{cite:321eeb17519d}}. But the firm argued this should not prove a material headwind for three reasons.

First, issuance as a percentage of total US equity market capitalization (roughly $72 trillion) is only slightly above the long-term average when measured against the Russell 3000 free float — a return to normal, not an aberration{{cite:321eeb17519d}}.

Second, buybacks totaled $1.2 trillion over the trailing twelve months and are expected to remain near that level through year-end. That means the corporate sector will likely buy back slightly more stock than it issues in aggregate, keeping net equity supply in negative territory — the opposite of Goldman’s projection{{cite:321eeb17519d}}.

Third, academic literature finds no consistent relationship between IPO activity and forward market returns. The five largest US-domiciled IPOs since 1990 showed no discernible effect on broader equity performance in the surrounding weeks. IPO activity is better understood as a coincident indicator: issuance rises when markets are strong, not a leading indicator of weakness{{cite:321eeb17519d}}.

The disagreement between Goldman and UBS on whether net supply turns flat or stays negative is not a trivial rounding error. It is the difference between “the 23-year tailwind is over” and “the 23-year tailwind is continuing, just at a slower pace.” Both cannot be right, and the answer determines whether the current issuance wave is a healthy normalization or the beginning of a structural repricing.

What Would Have to Be True for Each Side

If the structural-shift thesis is correct, several things must follow over the next 12–18 months: net equity supply turns positive as lock-ups expire in 2027; buyback announcements continue to decelerate as AI capex absorbs corporate cash; and the broad market’s price-to-earnings multiple faces organic pressure without the mechanical support of contracting share counts. We would also expect to see institutional portfolios rebalancing — selling existing holdings to make room for new issuance — which would show up as broader market weakness unrelated to any single company’s fundamentals.

If the UBS base-rate view is correct, what we are watching is a normal cyclical surge in issuance that coincides with strong markets, not a structural break. Buybacks remain the dominant force, net supply stays negative, and the SK hynix deal — however large — is absorbed the way Aramco’s was: with fanfare, with oversubscription, and without lasting damage to the broader market. The IPO pipeline thins when conditions weaken, as it always has, and the buyback engine reasserts itself once AI capex spending normalizes.

The honest assessment is that we are early in the test. SK hynix’s listing on July 10 is the first data point. The pace of secondary offerings through the third quarter is the second. Whether Meta follows Alphabet into the equity issuance market is the third. Each data point narrows the range of plausible outcomes.

What to Watch Next

• SK hynix (SKHY) debut, July 10: First-day trading performance and subsequent-week stability will signal whether the market absorbs the largest foreign IPO in US history without friction. Watch for any spillover selling in semiconductor and AI-adjacent names as institutions rebalance.

• Lock-up expiration calendar, 2027: Goldman’s projection that net supply turns positive hinges on 2026 IPO lock-ups releasing into the market. The first major expirations begin roughly six months post-listing — mark the first quarter of 2027 as the inflection window.

• Meta (META) secondary offering: If Meta proceeds with an equity raise comparable to Alphabet’s $85 billion, it confirms the hyperscaler shift from net buyer to net seller of stock. If it does not, the structural thesis weakens.

• Buyback announcement pace, Q3 2026: Quarterly buyback authorization data will reveal whether AI capex is genuinely crowding out repurchase programs or whether the $1.2 trillion trailing figure holds. A deceleration below the trailing average supports Goldman; stability near current levels supports UBS.

• IPO pipeline breadth beyond AI: The current issuance wave is heavily concentrated in AI and semiconductor names. If the pipeline broadens into healthcare, industrials, and consumer sectors through the back half of 2026, that signals healthy market-wide risk appetite. If it remains narrowly AI-focused, the market’s absorption capacity is being tested by a single theme.